In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 5166-5168

  Pankey, George ^a   Ashcraft, Deborah ^a   Patel, Nalini ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; E TEST METHOD; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; RIFAMPIN; VANCOMYCIN RESISTANCE;

EID: 28844466706     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.5166-5168.2005     Document Type: Article

References (22)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. 1a. Anonymous. 2005. Instructions to authors. Antimicrob. Agents Chemother. 49:1-20.
3. Archer, G. L., J. L. Johnston, G. J. Vazquez, and H. B. Haywood III. 1983. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev. Infect. Dis. 5(Suppl. 3):S538-S542.
4. Brandt, C. M., M. S. Rouse, B. M. Tallan, N. W. Laue, W. R. Wilson, and J. M. Steckelberg. 1995. Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis. Antimicrob. Agents Chemother. 39:1815-1819.
5. Caron, F., M. D. Kitzis, L. Gutmann, A. C. Cremieux, B. Maziere, J. M. Vallois, A. Saleh-Hghir, J. F. Lemeland, and C. Carbon. 1992. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. 36:2611-2616.
6. Cha, R., R. G. Gruez, Jr., and M. J. Rybak. 2003. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob. Agents Chemother. 47:1598-1603.
7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. CLSI document M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
8. Craven, N., and J. C. Anderson. 1981. Therapy of experimental staphylococcal mastitis in the mouse with cloxacillin and rifampicin, alone and in combination. Res. Vet. Sci. 31:295-300.
9. Critchley, I. A., R. S. Blosser-Middleton, M. E. Jones, C. Thornsberry, D. F. Sahm, and J. A. Karlowsky. 2003. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob. Agents Chemother. 47:1689-1693.
10. Dawis, M. A., H. D. Isenberg, K. A. France, and S. G. Jenkins. 2003. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J. Antimicrob. Chemother. 51:1203-1211.
11. Johnson, A. P., S. Mushtaq, M. Warner, and D. M. Livermore. 2004. Activity of daptomycin against multiresistant gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents 24:315-319.
12. Jorgensen, J. H., S. A. Crawford, C. C. Kelly, and J. E. Patterson. 2003. In vitro activity of daptomycin against vancomycin-resistant enterocooci of various Van types and comparison of susceptibility testing methods. Antimicrob. Agents Chemother. 47:3760-3773.
13. Lewis, R. E., D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49:345-351.
14. Lorian, V. (ed.). 1996. Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, Md.
15. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents. NCCLS document M26-A. NCCLS, Wayne, Pa.
16. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A6. NCCLS, Wayne, Pa.
17. Norden, C. W. 1983. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev. Infect. Dis. 5(Suppl. 3):S491-S494.
18. Oill, P. A., G. M. Kalmanson, and L. B. Guze. 1981. Rifampin, ampicillin, streptomycin, and their combinations in the treatment of enterococcal pyelonephritis in rats. Antimicrob. Agents Chemother. 20:491-492.
19. Pankey, G. A., and D. S. Ashcraft. 2005. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:2959-2964.
20. Rand, K. H., and H. Houck. 2004. Daptomycin synergy with rifampin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 53:530-532.
21. Smith, C. E., B. E. Foleno, J. F. Barrett, and M. B. Frosco. 1997. Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods. Diagn. Microbiol. Infect. Dis. 27:85-92.
22. Streit, J. M., R. N. Jones, and H. S. Sader. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J. Antimicrob. Chemother. 53:669-674.